-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dazodalibep in Kidney Transplant Rejection
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dazodalibep in Kidney Transplant Rejection report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dazodalibep in Kidney Transplant Rejection Drug Details: Dazodalibep (VIB-4920, MEDI-4920) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daxdilimab in Idiopathic Inflammatory Myopathy (IIM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daxdilimab in Idiopathic Inflammatory Myopathy (IIM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daxdilimab in Idiopathic Inflammatory Myopathy (IIM) Drug Details: Daxdilimab (VIB-7734,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daxdilimab in Dermatomyositis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daxdilimab in Dermatomyositis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daxdilimab in Dermatomyositis Drug Details: Daxdilimab (VIB-7734, MEDI-7734) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daxdilimab in Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daxdilimab in Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daxdilimab in Chronic Cutaneous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daxdilimab in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daxdilimab in Lupus Nephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daxdilimab in Lupus Nephritis Drug Details: Daxdilimab (VIB-7734, MEDI-7734) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daxdilimab in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daxdilimab in Alopecia Areata report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daxdilimab in Alopecia Areata Drug Details: Daxdilimab (VIB-7734, MEDI-7734) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fipaxalparant in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fipaxalparant in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fipaxalparant in Idiopathic Pulmonary Fibrosis Drug Details: Fipaxalparant (HZN-825) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fipaxalparant in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fipaxalparant in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fipaxalparant in Systemic Sclerosis (Scleroderma) Drug Details: Fipaxalparant (HZN-825) is under...
-
Product Insights
NewGlomerulonephritis – Drugs In Development, 2024
Empower your strategies with our Glomerulonephritis – Drugs In Development, 2024 report and make more profitable business decisions. Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat (strep throat), immune diseases such as lupus, type 1 and type 2 diabetes, and viral infections such as HIV, hepatitis B virus, and hepatitis C virus. Risk factors include family...